DAWNRAYS PHARMA announced its interim results, with a profit attributable to the parent company owners of approximately 105 million yuan, a year-on-year decrease of 78.79%

DAWNRAYS PHARMA announced its mid-year results for 2025, with a profit attributable to the parent company of approximately 105 million yuan, a year-on-year decrease of 78.79%. Revenue was approximately 630 million yuan, a year-on-year increase of 9.2%; gross profit was approximately 314 million yuan, a year-on-year decrease of 7.1%. In terms of sales, the sales volume of the antihypertensive "An" series products decreased by 5.7%, and sales revenue fell by 22.1%. The sales volume of the antiviral drug Entecavir dispersible tablets increased by 14.0%, and sales revenue grew by 8.7%. The overall profit decline was mainly due to the new factory not achieving scaled production, policy impacts, and increased R&D expenses